• Bothwell Beau 
  • Daniel E. Furst
Part of the Progress in Inflammation Research book series (PIR)


Hydroxychloroquine (C18H26C1N3O) and chloroquine, the two 4-aminoquinolones commonly prescribed for treatment in rheumatic diseases, are derived from the bark of the Peruvian cinchocha tree. Along with quinacrine, the two aminoquilones are labeled antimalarials after their long history in the treatment of that disease, highlighted by Pelletier and Caventou’s isolation of quinine and cinchonine as active antimalarial agents in 1820. Quinacrine, though not an aminoquinolone, carries within it the imbedded structure of chloroquine.


Rheumatoid Arthritis Systemic Lupus Erythematosus Systemic Lupus Erythematosus Patient Antirheumatic Drug Retinal Toxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Forrestier MJ (1929) L’aurotherapie dans les rhumatismes chroniques. Bull Mem Hop Paris 53: 323–327Google Scholar
  2. 2.
    Page F (1951) Treatment of lupus erythematosus with mepacrine. Lancet 2: 755CrossRefPubMedGoogle Scholar
  3. 3.
    Olson NY, Lindlsey CB (1989) Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J. Rheumatol 16: 12Google Scholar
  4. 4.
    Youssef W, Yan A, Russell A (1991) Palindromic rheumatism: a response to chloroquin. J. Rheumatol 18: 1Google Scholar
  5. 5.
    Carreno L, Lopez-Longo FJ, Gonzalez CM, Monteagudo I (2002) Treatment options for juvenile-onset systemic lupus erythematosus. Paediatr Drugs 4 (4): 241–256PubMedGoogle Scholar
  6. 6.
    Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Brenndan Moore S (1988) Eosinophilic fascitis: Clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 17: 221CrossRefPubMedGoogle Scholar
  7. 7.
    McKendry RJ, et al [unpublished]Google Scholar
  8. 8.
    Ausiello C, Sorrentino V, Ruggiero V, Rossi GB (1984) Action of lyosomotropic amines on spontaneous and interf er on-enhanced NK and CTL cytolysis. Immuno Lett 8: 11CrossRefGoogle Scholar
  9. 9.
    Ausiello CM, Barbieri P, Spagnoli GC, Ciompi ML, Casciani CU (1986) In vivo effects of chloroquine treatment on spontaneous and interferon-induced natural killer activities in rheumatoid arthritis patients. Clin Exp Rheumatol 1: 255Google Scholar
  10. 10.
    Fox RI (1993) Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arth Rheum 2 (Supp 1) 82–91Google Scholar
  11. 11.
    Espinola RG, Pierangeli SS, Ghara AE, Harris EN (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87 (3): 518–522PubMedGoogle Scholar
  12. 12.
    Liu ST, Wang CR, Yin GD, Liu MF, Lee GL, et al (2001) Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus. Asian Vac J Allergy Immunol 19 (1): 29–35Google Scholar
  13. 13.
    Nishihara KK, Fürst DE (1995) Hydroxychloroquine and its use in rheumatoid arthritis. Today’s Therapeutic Trends 13: 109–124Google Scholar
  14. 14.
    Ciak J, Hahn FE (1966) Chloroquine: mode of action. Science 151: 347–351CrossRefPubMedGoogle Scholar
  15. 15.
    Krogstad DJ, Schlesinger MD (1987) Acid-vesicle function, intracellular pathogens and the action of chloroquine against plasmodium falciparum. New Engl J Med 317: 542–559PubMedCrossRefGoogle Scholar
  16. 16.
    Tupule A, Krishnaswamy K (1982) Effect of food on the bioavailability of chloroquine. Eur J Clin Pharmacol 23: 271–273CrossRefGoogle Scholar
  17. 17.
    Tett SE (1993) Clinical pharmacology of slow acting antirheumatic drugs. Clin Pharmacokinetics 25: 392–407CrossRefGoogle Scholar
  18. 18.
    Munster T, Gibbs JP, Shen D, Baethge BA, Bostein GR, Fürst DE et al (2002) Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 46 (6): 1460–1469CrossRefPubMedGoogle Scholar
  19. 19.
    Bernstein H, Zvaifler N, Rubin M, Mansou Am (1963) The ocular deposition of chloroquine. Invest Ophthalmol 1: 384–392Google Scholar
  20. 20.
    Somer M, Kallio J, Pesonen U, Pyyko K, Huupponen R et al (2000) Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol 49 (6): 549–454CrossRefPubMedGoogle Scholar
  21. 21.
    Carmichael SJ, Beal J, Day RO, Tett SE (2002) Combination therapy with methotrexate and hydroxychloroquin for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 29 (10): 2077–2083PubMedGoogle Scholar
  22. 22.
    Clark P, Casas E, Tugwell P et al (1993) Hydroxychloroquine compared with placebo in rheumatoid arthritis. Annals of Internal Medicine 119: 1067–1071PubMedGoogle Scholar
  23. 23.
    Suarez-Almazor ME, Beiseck E, Shea B et al (2000) Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 4: CD000959Google Scholar
  24. 24.
    Mackenzie AH (1983) Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 75: (Suppl) 40CrossRefPubMedGoogle Scholar
  25. 25.
    Fürst DE, Lindsley H, Baethge B, Botstein GR, Caldwell J et al (1999) Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized double-blind six-week trial with eighteen-week extension. Arthritis Rheum 42 (2): 357–365CrossRefPubMedGoogle Scholar
  26. 26.
    Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H et al (2002) Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46 (4): 894–898CrossRefPubMedGoogle Scholar
  27. 27.
    Hurst S, Kalian MJ, Wolfe FJ, Fries JF, Albert DA (2002) Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. J. Rheumatol 29 (8): 1639–1645PubMedGoogle Scholar
  28. 28.
    Jessop, JD, O’Sullivan MM, Lewis PA, Williams LA, Camilleri JP et al (1998) A long term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. Br J Rheumatol 37 (9): 992–1002CrossRefPubMedGoogle Scholar
  29. 29.
    Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV et al (2002) Disease modifying antirheumatic drugs in early rheumatoid arthritis: a long term observational study. J. Rheumatol 29 (2): 261–266PubMedGoogle Scholar
  30. 30.
    Griffiths RI, Bar-Din M, MacLean C, Sullivan EM, Herbert RJ et al (2001) Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients. Ther Apher 5 (2): 92–104CrossRefPubMedGoogle Scholar
  31. 31.
    Avina-Zubieta JA, Galindo-Rodriquez G, Newman S et al (1998) Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 57 (10): 582–587CrossRefPubMedGoogle Scholar
  32. 32.
    Marguerie L, Flipo RM, Grardel B et al (2002) Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine 69 (3): 275–281CrossRefPubMedGoogle Scholar
  33. 33.
    Cornbleet T (1956) Action of synthetic antimalarial drugs on psoriasis. J. Invest Dermatol 26: 435–436PubMedGoogle Scholar
  34. 34.
    Luzat MJ (1982) Hydroxychloroquine in psoriatic arthropathy: Exacerbations of psoriatic skin lesions. J. Rheumatol 9: 462–464Google Scholar
  35. 35.
    Bryant LR, des Rosier KF, Carpenter MT (1995) Hydroxychloroquine in the treatment of erosive osteoarthritis. J. Rheumatol 22 (8): 1527–1531PubMedGoogle Scholar
  36. 36.
    van Jaarsveld CH, Jahangier ZN, Jacobs JW, Blaauw A A, van Albada-Kuipers GA et al (2000) Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. Rheumatology (Oxford) 39 (12): 374]Google Scholar
  37. 37.
    Wang C, Fortin PR, Li Y, Panaritis T, Gans M et al (1999) Discontinuation of antimalarial drugs in systemic lupus erythematosus. J. Rheumatol 26 (4): 808–815PubMedGoogle Scholar
  38. 38.
    Fries JF, Williams CA, Ramey D (1993) The relative toxicity of disease modifying antirheumatic drugs. Arthritis Rheum 36: 297–306CrossRefPubMedGoogle Scholar
  39. 39.
    Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second line drugs in rheumatoid arthritis. Results of two meta-analysis. Arthritis Rheum 33:1449–1461CrossRefPubMedGoogle Scholar
  40. 40.
    Fellahi JL, Dumazer P, Delayance S et al (1993) Cardiomyopathy under treatment with hydroxychloroquine disclosed by complete auriculoventricular block. Rev Med Interne 14 (4): 275–276CrossRefPubMedGoogle Scholar
  41. 41.
    Propp RP, Stillman JS (1967) Agranulocytosis and hydroxychloroquine. N Engl J Med 277: 492–493PubMedGoogle Scholar
  42. 42.
    Easterbrook M (1993) The ocular safety of hydroxychloroquine. Semin Arthritis Rheum 23 (Suppl 1) 62–67PubMedCrossRefGoogle Scholar
  43. 43.
    Nord JE, Shah PK, Rinaldi RZ, Weisman MH (2004) Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 33: 336–351CrossRefPubMedGoogle Scholar
  44. 44.
    Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A et al (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: A reappraisal. Ophthalmology 110 (7): 1321–1326CrossRefPubMedGoogle Scholar
  45. 45.
    Easterbrook M (1999) An ophthalmological view on the efficacy and safety of chloroquine versus hydroxchloroquine. J. Rheumatol 26 (9): 1866–1868PubMedGoogle Scholar
  46. 46.
    Berliner RW, Earl DP Jr, Taggart JV, Zubrod CG, Welch WJ et al (1948) Studies on the chemotherapy of human malarious. VI. The physiologic deposition, antimalarial activity and toxicity of several derivatives of 4-aminoquinolones. J. Clin Invest 27 (Supp): 98–110CrossRefGoogle Scholar
  47. 47.
    Hobbs HE, Calnan DC (1958) The ocular complications of chloroquine therapy. Lancet 1: 1207–1209CrossRefPubMedGoogle Scholar
  48. 48.
    Borden MB, Parke AL (2001) Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf 24 (14): 1055–1063CrossRefPubMedGoogle Scholar
  49. 49.
    Costedoat-Chalumeau N, Amoura Z, Duhaut P et al (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 48 (11): 3207–3211CrossRefPubMedGoogle Scholar
  50. 50.
    Saraux A, Berthelot JM, Charles G, Le HC, Thorel J et al (2002) Second-line drugs used in recent-onset rheumatoid arthritis in Brittany (France). Joint Bone Spine 69 (1): 37–42CrossRefPubMedGoogle Scholar
  51. 51.
    Erkan D, Yaziei Y, Harrison MJ, Paget SA (2002) Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first line therapy. Arthritis Rheum 15: 47(3): 285–290CrossRefPubMedGoogle Scholar
  52. 52.
    Prashker MJ, Meenan RF (1995) The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 38 (3): 318–325CrossRefPubMedGoogle Scholar
  53. 53.
    Pope JE, Hong P, Kochler BE (2002) Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. J. Rheumatol 29 (2): 255–260PubMedGoogle Scholar
  54. 54.
    Finbloom DS, Silver K, Newsome DA et al (1985) Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J. Rheumatol 12: 692–694PubMedGoogle Scholar
  55. 55.
    ABPI Data Sheet Compendium (1994–1995) Datapharm Publications Ltd, London 1445–1446Google Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2005

Authors and Affiliations

  • Bothwell Beau 
    • 1
  • Daniel E. Furst
    • 2
  1. 1.The David Geffen School of Medicine, Division of RheumatologyUniversity of California at Los AngelesLos AngelesUSA
  2. 2.Carl M.Pearson Professor of RheumatologyLos AngelesUSA

Personalised recommendations